V. Karanikas

Immunology · 2016–2018

A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 48 citations into it
• Oncology — 46 citations into it

Whom V. Karanikas trusts

Their strongest outbound trust, strongest first, inferred from their citations.

1. D. Pardoll (in Oncology)

Papers from V. Karanikas's perspective

Ordered by how strongly the researchers V. Karanikas trusts endorse each paper. Same corpus, a different order for every researcher.

1. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
2. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
4. PD-1 blockade in tumors with mismatch repair deficiency. (Journal of Clinical Oncology)
5. Signatures of mutational processes in human cancer (Nature)
6. An immune-active tumor microenvironment favors clinical response to ipilimumab (Cancer Immunology and Immunotherapy)
7. PD-1 blockade induces responses by inhibiting adaptive immune resistance (Nature)
8. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (Journal of Clinical Oncology)
9. The future of immune checkpoint therapy (Science)
10. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)

Their papers

• A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade (2018) — 1,018 citations
• The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition (2016) — 788 citations